Advertisement
Singapore markets close in 3 hours 3 minutes

  • Straits Times Index

    3,173.60
    -14.06 (-0.44%)
     

  • Nikkei

    37,138.59
    -941.11 (-2.47%)
     

  • Hang Seng

    16,159.80
    -226.07 (-1.38%)
     

  • FTSE 100

    7,877.05
    +29.06 (+0.37%)
     

  • Bitcoin USD

    62,088.85
    +691.91 (+1.13%)
     

  • CMC Crypto 200

    1,281.07
    +395.53 (+43.18%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • Dow

    37,775.38
    +22.07 (+0.06%)
     

  • Nasdaq

    15,601.50
    -81.87 (-0.52%)
     

  • Gold

    2,395.70
    -2.30 (-0.10%)
     

  • Crude Oil

    84.33
    +1.60 (+1.93%)
     

  • 10-Yr Bond

    4.6470
    0.0000 (0.00%)
     

  • FTSE Bursa Malaysia

    1,551.42
    +6.66 (+0.43%)
     

  • Jakarta Composite Index

    7,063.10
    -103.72 (-1.45%)
     

  • PSE Index

    6,426.36
    -96.83 (-1.48%)
     

AstraZeneca's Lynparza fails in gastric cancer combination test

Reuters
A man walks past a sign at an AstraZeneca site in Macclesfield, central England May 19, 2014. REUTERS/Phil Noble/File Photo

LONDON (Reuters) - AstraZeneca's (AZN.L) recently approved ovarian cancer drug Lynparza failed to increase overall survival significantly when given with chemotherapy to patients with gastric cancer in a late-stage trial, the drugmaker said on Wednesday.

The news is a setback for the British drugmaker, which reported positive results with an experimental acute asthma drug on Tuesday, although the result may have limited read-across for Lynparza in other cancer settings.

AstraZeneca said it was disappointed, but noted this particular trial was unusual in using a low dose and combining Lynparza with a standard chemotherapy.

The company has high hopes for Lynparza, which is central to its goal of building a portfolio of compounds targeting DNA damage response (DDR) mechanisms in cancer cells.

(Reporting by Ben Hirschler; Editing by Mark Potter)